Trust Co. of Vermont Cuts Position in Pfizer Inc. $PFE

Trust Co. of Vermont lessened its position in Pfizer Inc. (NYSE:PFE) by 14.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 184,643 shares of the biopharmaceutical company’s stock after selling 32,076 shares during the quarter. Trust Co. of Vermont’s holdings in Pfizer were worth $4,598,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the business. Peak Asset Management LLC increased its position in shares of Pfizer by 1.4% during the second quarter. Peak Asset Management LLC now owns 28,768 shares of the biopharmaceutical company’s stock worth $697,000 after acquiring an additional 402 shares during the period. Quest Investment Management LLC raised its position in Pfizer by 1.3% in the 3rd quarter. Quest Investment Management LLC now owns 31,768 shares of the biopharmaceutical company’s stock valued at $809,000 after purchasing an additional 405 shares in the last quarter. Community Bank & Trust Waco Texas raised its position in Pfizer by 0.6% in the 3rd quarter. Community Bank & Trust Waco Texas now owns 66,841 shares of the biopharmaceutical company’s stock valued at $1,703,000 after purchasing an additional 412 shares in the last quarter. CVA Family Office LLC boosted its stake in shares of Pfizer by 3.3% in the 3rd quarter. CVA Family Office LLC now owns 12,915 shares of the biopharmaceutical company’s stock valued at $329,000 after buying an additional 413 shares during the period. Finally, Boltwood Capital Management grew its position in shares of Pfizer by 0.7% during the third quarter. Boltwood Capital Management now owns 58,274 shares of the biopharmaceutical company’s stock worth $1,485,000 after buying an additional 420 shares in the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Wolfe Research set a $24.00 target price on shares of Pfizer and gave the stock an “underperform” rating in a research note on Wednesday, December 17th. Morgan Stanley set a $27.00 price target on shares of Pfizer and gave the stock a “positive” rating in a report on Tuesday, March 17th. Barclays initiated coverage on shares of Pfizer in a research report on Thursday, February 19th. They issued an “underweight” rating and a $25.00 price objective on the stock. Royal Bank Of Canada began coverage on shares of Pfizer in a report on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price objective on the stock. Finally, Daiwa Securities Group cut Pfizer from an “outperform” rating to a “neutral” rating and set a $27.00 target price for the company. in a research note on Thursday, February 12th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, thirteen have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and a consensus price target of $28.19.

Pfizer Trading Up 1.7%

Shares of Pfizer stock opened at $28.56 on Thursday. The company has a market capitalization of $162.41 billion, a P/E ratio of 21.00 and a beta of 0.43. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $28.64. The company’s fifty day moving average is $26.99 and its two-hundred day moving average is $25.77. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 EPS for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the prior year, the business earned $0.63 EPS. The firm’s revenue was down 1.2% compared to the same quarter last year. Analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Belgian court ordered Poland and Romania to accept €1.9B (~$2.2B) of Pfizer COVID-19 vaccines, effectively locking in substantial near-term revenue and reducing delivery/collection uncertainty. Belgian court orders Poland, Romania to buy $2.2 billion of Pfizer COVID vaccines
• Positive Sentiment: Analyst/market write-ups highlight PFE’s recent outperformance and upward technical momentum (trading above its 50- and 200-day SMAs, and positive earnings beats), which supports demand for the stock. Why Pfizer (PFE) Outpaced the Stock Market Today
• Positive Sentiment: Fresh real?world data from a Swedish study on Ibrance (palbociclib) offers an incremental clinical signal for Pfizer’s oncology franchise, supporting pipeline upside expectations. Pfizer’s Swedish Ibrance Study: Fresh Real?World Data Signal for PFE Investors
• Neutral Sentiment: Pfizer finalized reshaping of ViiV Healthcare ownership (GSK/Shionogi deal) as it exits the joint HIV venture — a strategic reallocation that may free capital but reduces direct exposure to that HIV business. GSK and Shionogi Reshape ViiV Healthcare Ownership as Pfizer Exits HIV Venture
• Neutral Sentiment: Background and business-model pieces continue to circulate (how Pfizer makes money, sector commentary), useful for context but not immediate catalysts. How Pfizer Makes Money
• Negative Sentiment: Pfizer and BioNTech paused U.S. recruitment for a large updated COVID vaccine trial (adults 50–64) due to low enrollment — a setback for collecting pivotal U.S. data and could delay future vaccine updates or label expansion. Exclusive: Pfizer, BioNTech halt US COVID vaccine study after recruitment struggles
• Negative Sentiment: Critical pieces argue Pfizer’s large dividend may mask underlying growth challenges, keeping longer-term valuation concerns on investors’ radar. Bearish on Pfizer (PFE) as Big Dividend Fails to Mask the Growth Problem
• Negative Sentiment: Reports that Pfizer will close its South San Francisco research site may signal internal cost-cutting or pipeline reprioritization; this can be seen as short-term disruption to R&D capacity. Pfizer is said to close South San Francisco research site

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.